繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 新药动态 >> Nanoxel-PM(注射用多西他赛胶束)

Nanoxel-PM(注射用多西他赛胶束)

2014-10-31 15:08:55  作者:新特药房  来源:互联网  浏览次数:233  文字大小:【】【】【
简介:Product: Nanoxel PM Generic Name: docetaxel Therapeutic Subcategory: Alkaloids Samyang Biopharm was established on November 1, 2011, when Samyang Group shifted into a holding company sy ...

Product: Nanoxel PM
Generic Name:   docetaxel
Therapeutic Subcategory:     Alkaloids

Samyang Biopharm was established on November 1, 2011, when Samyang Group shifted into a holding company system, spinning off Samyang Corp.'s Pharmaceutical/Bio Business Division. Samyang Biopharm Pharmaceutical/Bio Business Division is one of the three major growth engines of Samyang Group, together with the chemical and foodstuff divisions. As such, the company has been investing over 30% of its annual sales into R&D since 1995, when it entered the pharmaceutical/bio businesses, thus developing DDS and other new drug technologies, as well as new formulae. It has developed and is currently selling anti-cancer drugs such as Genexol® and Nanoxel®M, the smoking cessation patch NicoStop®, and biodegradable sutures such as Trisorb® and Monosorb®.
In particular, the anti-cancer drugs Genexol®PM and Nanoxel®PM, adopting the research institute's self-developed technology DDS, show excellent efficacies, such as reduced adverse effects. Our biodegradable sutures are the world's third-developed items of their kind and are exported to 130 clients in 80 countries. Samyang Biopharm is currently constructing a pharmaceutical/bio R&D center on a 1,750-pyeong area in the Pangyo new town's Techno Valley, with an investment of KRW150 billion. The center is expected to be completed by 2015. This center will be Samyang Biopharm's research hub and will drive it to become a global pharmaceutical company.
Furthermore, in recognition of its R&D investment and technology, Samyang Biopharm was certified as an innovative pharmaceutical company by the Ministry of Health and Welfare in 2012. We endeavor to continuously research on, develop, and sell drugs and medical devices that promote good human health and that enrich the quality of human life. By so doing, we vow to become a company that can be completely trusted by our customers, an innovative company pioneering new values, and a company that fosters talents, and to grow as a global pharmaceutical company.

About Samyang Biopharm
CEO Gwak Cheol-ho
Inception October 1924
Address #31 Jongno 33-gil, Jongno-gu, Seoul
Tel. Nil
Website www.samyangbiopharm.com

责任编辑:admin


相关文章
 

最新文章

更多

· 难治多发性骨髓瘤新药ix...
· 多发性骨髓瘤新药Faryda...
· FDA批准Varubi片用于化疗...
· 抗癌新药Odomzo(sonide...
· 白血病新药venetoclax获...
· 欧盟批准Vectibix用于转...
· 新类抗基底细胞癌药物Od...
· 新类肺癌靶向药物Iressa...
· 新型口服抗癌药Lenvima(...
· FDA批准CYRAMZA(ramucir...

推荐文章

更多

· 难治多发性骨髓瘤新药ix...
· 多发性骨髓瘤新药Faryda...
· FDA批准Varubi片用于化疗...
· 抗癌新药Odomzo(sonide...
· 白血病新药venetoclax获...
· 欧盟批准Vectibix用于转...
· 新类抗基底细胞癌药物Od...
· 新类肺癌靶向药物Iressa...
· 新型口服抗癌药Lenvima(...
· FDA批准CYRAMZA(ramucir...

热点文章

更多

· FDA批准Varubi片用于化疗...
· 难治多发性骨髓瘤新药ix...
· 多发性骨髓瘤新药Faryda...